Clinical study to investigate whether tofogliflozin increased plasma magnesium level regulates sympathetic tone in type 2 diabetes
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000048055
- Lead Sponsor
- Shimane University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Not provided
Those patients who meet one of the following criteria are excluded: 1. Patients with type 1 diabetes, or secondary diabetes 2. Patients with poor blood glucose control (HbA1c 10% or above) 3. Patients who are taking the medication with magnesium (including Mg supplement) 4. Patients who are taking loop diuretic or thiazide diuretic agents 5. Patients with serious liver functional impairment (AST:100 or above) 6. Patients with moderate to severe heart failure (class 3 or worse based on the New York Heart Association (NYHA)Functional Classification) 7. Patients with urinary tract infection, or genital infection 8. Patients who are pregnant, possibly pregnant, nursing, or planning to conceive a child 9. Patients with a malignant tumor or have a history of malignant tumor (exceptions: those are not on medication for malignant tumor, and have no recurrence of the disease so far and without recurrence risks during this study are allowed to participate) 10. Patients who are prohibited to use tofogliflozin 11. Other patients determined ineligible by an investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method